Low Tidal Volume Strategy In Cardiogenic Pulmonary Edema: The Logical Trial (LOGICAL)
Some people with heart failure develop fluid buildup in the lungs and need a breathing machine while they are treated in an intensive care unit. The amount of air delivered with each breath may affect how quickly they recover.
The LOGICAL study will compare two ways of setting the breathing machine: delivering a lower or an intermediate amount of air with each breath. About 300 adults in intensive care units across Spain will be randomly assigned to one of these strategies.
The study aims to find out whether the lower amount of air increases the number of days patients are alive and breathing without the machine during the first 28 days after assignment. The researchers will also assess other outcomes, including survival and length of stay in the intensive care unit and hospital.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Dr Laura Amado-Rodríguez
- 電話番号:+34 985108000
- メール:laura.amado@sespa.es
研究連絡先のバックアップ
- 名前:Dr Miguel Ángel Rodríguez Yago
- 電話番号:+34 985108000
- メール:miguelangel.rodriguezyago@gmail.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Admission to a participating intensive care unit (ICU).
-
Within the first 24 hours of invasive mechanical ventilation, whether ventilation was started before or after admission to the participating ICU.
-
Expected duration of invasive mechanical ventilation greater than 24 hours.
-
Acute hypoxemic respiratory failure of cardiogenic origin, meeting all three of the following criteria:
-
PaO2/FiO2 ratio below 300 mmHg.
-
Pulmonary congestion shown by at least one of the following:
- Lung ultrasound showing multiple B-lines (at least 3 per zone), distributed bilaterally in at least 2 zones per hemithorax; or
- Chest radiograph showing interstitial or alveolar edema, vascular redistribution, or Kerley B-lines.
-
Evidence of a cardiogenic origin shown by at least one of the following:
- Echocardiographic evidence of elevated left-sided filling pressures (E/e' >14 or E/A >2); or
- Pulmonary capillary wedge pressure >15 mmHg measured with a pulmonary artery catheter.
-
Exclusion Criteria:
- Participation in another interventional clinical trial.
- More than 24 hours of invasive mechanical ventilation.
- Extracorporeal support already initiated.
- Expected extubation within the next 24 hours.
- A predominantly noncardiogenic cause of acute respiratory failure, including acute respiratory distress syndrome, active pneumonia or other pulmonary infection, confirmed pulmonary embolism, or acute lung injury of noncardiac origin.
- Pregnancy.
- Risk of or suspected elevated intracranial pressure.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV chronic obstructive pulmonary disease.
- Known pre-existing interstitial lung disease.
- Previous pneumonectomy or lobectomy.
- Terminal condition, a decision to limit life-sustaining treatment, or a do-not-resuscitate order.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Low Tidal Volume Ventilation
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 ml/kg of predicted body weight. Tidal volume may be reduced to 4 ml/kg according to respiratory mechanics and clinical tolerance. |
Volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 mL/kg of predicted body weight. Tidal volume may be reduced stepwise to 4 mL/kg according to respiratory mechanics and clinical tolerance. |
|
アクティブコンパレータ:Intermediate Tidal Volume Ventilation
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining airway pressures within the protocol-defined safety limits. |
Volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining plateau pressure below 30 cmH₂O and driving pressure below 15 cmH₂O. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Days Alive and Free of Invasive Mechanical Ventilation Through Day 28
時間枠:From randomization through day 28
|
Number of days from randomization through day 28 that a participant is alive and free of invasive mechanical ventilation. Participants who die before day 28 are assigned 0 days. Higher values indicate a more favorable outcome. |
From randomization through day 28
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-Cause Mortality at Day 28
時間枠:From randomization through day 28
|
Percentage of participants who die from any cause within 28 days after randomization. |
From randomization through day 28
|
|
Duration of Invasive Mechanical Ventilation
時間枠:From randomization until successful liberation, death, or day 90
|
Time from randomization to successful liberation from invasive mechanical ventilation, defined as remaining free of invasive mechanical ventilation for at least 48 hours. Death before liberation will be considered a competing event in the analysis. |
From randomization until successful liberation, death, or day 90
|
協力者と研究者
スポンサー
スポンサー
協力者
協力者
捜査官
捜査官
- 主任研究者:Laura Amado-Rodríguez, MD, PhD、Hospital Universitario Central de Asturias
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- LOGICAL Trial
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The investigators intend to explore sharing anonymized individual participant data after publication of the main results, subject to ethical approval, applicable data protection requirements, and assessment of re-identification risk. The specific data sets, access process, and availability period have not yet been determined.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。